The benefit of deferred carotid revascularization in patients with moderate-severe disabling cerebral ischemic stroke.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
01 2021
Historique:
received: 23 12 2019
accepted: 18 03 2020
pubmed: 30 4 2020
medline: 4 5 2021
entrez: 30 4 2020
Statut: ppublish

Résumé

Symptomatic carotid artery stenosis needs revascularization within 2 weeks by carotid endarterectomy (CEA) to reduce the risk of symptom recurrence; however, the optimal timing of intervention is yet to be defined in patients with large-volume cerebral ischemic lesion (LVCIL) and modified Rankin scale (mRS) score ≥3. The aim of this study was to determine the most appropriate timing for CEA in patients with a recent stroke and LVCIL. Data from patients with symptomatic carotid stenosis with LVCIL and mRS score of 3 or 4 from 2007 to 2017 were considered. Patients were submitted to CEA if they had a stable clinical condition and life expectancy >1 year. LVCIL was defined as a cerebral ischemic lesion of volume >4000 mm In an 11-year period, of a total 4020 CEAs, 126 (2.9%) were performed in patients with a moderate stroke and LVCIL occurring in the same admission. The patients' median age was 69 years (interquartile range [IQR], 10 years); 72% (91) were male, with mRS score of 3 (IQR, 1) and LVCIL volume of 20,000 mm The surgical risk of CEA in patients with a recent moderate-severe ischemic stroke and LVCIL is high. However, if the intervention is delayed >4 weeks, its benefit seems significant.

Identifiants

pubmed: 32348801
pii: S0741-5214(20)30597-8
doi: 10.1016/j.jvs.2020.03.043
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-124

Informations de copyright

Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Rodolfo Pini (R)

Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola-Malpighi, Bologna, Italy.

Gianluca Faggioli (G)

Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola-Malpighi, Bologna, Italy. Electronic address: gianluca.faggioli@unibo.it.

Andrea Vacirca (A)

Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola-Malpighi, Bologna, Italy.

Mortalla Dieng (M)

Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola-Malpighi, Bologna, Italy.

Martina Goretti (M)

Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola-Malpighi, Bologna, Italy.

Enrico Gallitto (E)

Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola-Malpighi, Bologna, Italy.

Chiara Mascoli (C)

Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola-Malpighi, Bologna, Italy.

Jean-Baptiste Ricco (JB)

Direction de la Recherche Clinique et de l'Innovation, CHU de Poitiers, DRC, Poitiers, France.

Mauro Gargiulo (M)

Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola-Malpighi, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH